Armistice Capital, LLC
CIK:0001601086
Hedge Fund
$6B AUM
205 holdings
New York, NY, United States
Armistice Capital, LLC is a hedge fund headquartered in New York, NY. Founded in 2012, the firm manages significant assets on behalf of institutional investors and high-net-worth individuals. Armistice Capital specializes in long/short equity strategies, primarily focusing on U.S. publicly traded companies. The firm has approximately 30 employees.
Investment Strategy
Armistice Capital employs a long/short equity investment strategy with an emphasis on U.S. securities. The fund actively manages a diverse portfolio and uses derivatives, such as put options, to hedge or enhance positions. It frequently invests in sectors like pharmaceuticals and retail, with position sizes reflecting fundamental analysis and a flexible approach to market conditions.
Top Buys
G
GEHCGE HEALTHCARE TECHNOLOGIES I+$31.6M
M
MCDMCDONALDS CORP+$29.5M
I
IBRXIMMUNITYBIO INC+$20.5M
G
GTLBGITLAB INC+$14.6M
M
MDBMONGODB INC+$13.8M
Top Sells
S
SPBSPECTRUM BRANDS HLDGS INC NE-$49.4M
S
SMPLSIMPLY GOOD FOODS CO-$46.6M
P
PTCTPTC THERAPEUTICS INC-$45.7M
S
SAMBOSTON BEER INC-$44.9M
D
DPZDOMINOS PIZZA INC-$41.4M
Top Holdings
P
PTCTPTC THERAPEUTICS INC+4.0%$231.3M
S
SUPNSUPERNUS PHARMACEUTICALS INC+2.6%$151.7M
T
TVTXTRAVERE THERAPEUTICS INC+2.3%$131.4M
I
INCYINCYTE CORP+1.6%$91.0M
N
NBIXNEUROCRINE BIOSCIENCES INC+1.5%$85.0M
Equity Positions (177)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
P PTCT | PTC THERAPEUTICS INC | 3.99% | $231.3M | 4,735,464 | $31.13 | $48.84 | -$45.7M |
S SUPN | SUPERNUS PHARMACEUTICALS INC | 2.62% | $151.7M | 4,812,000 | $26.36 | $31.52 | -$18.5M |
T TVTX | TRAVERE THERAPEUTICS INC | 2.27% | $131.4M | 8,876,000 | $19.90 | $14.80 | -$27.6M |
I INCY | INCYTE CORP | 1.57% | $91.0M | 1,336,000 | $59.91 | $68.10 | -$10.2M |
N NBIX | NEUROCRINE BIOSCIENCES INC | 1.47% | $85.0M | 676,024 | $126.71 | $125.69 | -$25.7M |
Options Positions (5)
| Ticker | Security | Action | Type | Notional Value | Contracts | Underlying Price | Premium Paid | Change (Contracts) | Change (Value) |
|---|---|---|---|---|---|---|---|---|---|
S SPY | SPDR S&P 500 ETF TR | — | Put | $1.51B | 24,500 | $617.85 | $425.62 | 0 | +$143.2M |
I IWM | ISHARES TR | Bought | Put | $1.51B | 70,000 | $215.79 | $191.99 | +3,000 | +$173.9M |
M MDGL | MADRIGAL PHARMACEUTICALS INC | Sold | Call | $51.4M | 1,700 | $302.64 | $331.23 | -1,300 | -$47.9M |
C CYTK | CYTOKINETICS INC | Sold | Call | $44.3M | 13,400 | $33.04 | $44.55 | -13,600 | -$64.2M |
F FIVN | FIVE9 INC | New | Call | $37.6M | 14,200 | $26.48 | $26.48 | +14,200 | +$37.6M |
Industry Allocation
PHARMACEUTICAL PREPARATIONS
+19.9%
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
+5.2%
SERVICES-PREPACKAGED SOFTWARE
+3.1%
SERVICES-COMPUTER PROCESSING & DATA PREPARATION
+2.1%
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
+2.0%
Investment Team (5)
| Name | Role | Location | |
|---|---|---|---|
J Jason Glass | Managing Director | New York, NY , United States | |
 | Vice President | Ramsey, NJ , United States | |
S Steven Boyd | Managing Partner | New York, NY , United States | |
 | Partner, Consumer Sector Head and Portfolio Manager | New York, NY , United States | |
K Keith Maher | Managing Director | New York, NY , United States |